CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 771 enrolled
Drug / intervention
Raphamin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05364671
NCT05364671Phase 3Completed
CompareCT.gov

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Materia Medica Holding·interventional·Posted May 6, 2022·Updated Jan 6, 2025

In Brief

A Phase 3 clinical trial evaluating Raphamin and Placebo for Coronavirus Disease 2019 (COVID-19). Completed, enrolled 771 participants across 36 sites.

Detailed Summary

Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 (COVID-19)
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMay 6, 2022
Enrollment StartApr 29, 2022
Primary CompletionAug 18, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago

Interventions

Raphamindrug

Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.

Placebodrug

Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.